TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3080269
Drug: Ibuprofen +
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen + Ethanol
Study: 24195623
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Lactobacillus gasseri OLL2809
Study: 24195623
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Lactobacillus gasseri OLL2809 + 900 mg α-lactalbumin
Study: 12663512
Drug: Kiwifruit supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kiwifruit supplementation (specific dosage not mentioned) for 3-week periods
Study: 12663512
Drug: Kiwifruit supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kiwifruit supplementation (specific dosage not mentioned)
Study: 10887107
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of genetically modified CD8(+) T cells (10(10) cells)
Study: 10887107
Drug: Second series
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second series of infusions of both CD4(+) and CD8(+) T cells engineered to express the chimeric receptor, costimulated ex vivo with beads coated with anti‐CD3 and anti‐CD28
Study: 10887107
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of modified CD4(+) and CD8(+) T cells together after ex vivo costimulation
Study: 8813788
Drug: High-dose preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose preoperative radiotherapy (5 x 5 Gy)
Study: 31025930
Drug: tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: tocilizumab 8 mg/kg intravenously at study begin and weeks 4, 8, and 12
Study: 31025930
Drug: rituximab 1000
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab 1000 mg at weeks 16 and 18
Study: 30334433
Drug: Oral Probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Probiotics
Study: 27155493
Drug: PCV13 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 plus trivalent inactivated influenza vaccine
Study: 22330975
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (short leg cast or brace and protected weight bearing for 6 weeks)
Study: 16248728
Drug: Within-compound associations
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within-compound associations
Study: 11790236
Drug: High-dose creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose creatine (150 mg/kg daily)
Study: 8720287
Drug: Ribavirin alone
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin alone (15 mg/kg daily for 6 months)
Study: 8720287
Drug: Interferon alone
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alone (3 MU thrice weekly for 6 months)
Study: 8720287
Drug: Interferon plus
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon plus ribavirin (at above doses)
Study: 1451730
Drug: 0.07 mg
Normalized name: urea 0.07 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg digitoxin o.d. for up to 58 days
Study: 1451730
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral captopril b.d. (concomitant administration)
Study: 29128648
Drug: ED-initiated Screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED-initiated Screening, Brief Intervention, and Referral for Treatment (SBIRT) focused on HTN
Study: 26179360
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec and insulin degludec/insulin aspart
Study: 26179360
Drug: Basal‐oral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal‐oral therapy
Study: 26179360
Drug: Type 2
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 2 diabetes multiple daily injections
Study: 22471899
Drug: Topical fucidic
Normalized name: Fucidin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fucidic acid plus betamethasone valerate cream
Study: 22471899
Drug: Topical fucidic
Normalized name: Fucidin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fucidic acid (control group)
Study: 12755663
Drug: Ziprasidone (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (40-160 mg/day)
Study: 15610070
Drug: Bosentan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (500 mg orally 2 hours before ischaemia)
Study: 12392582
Drug: Subcutaneous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous midazolam (0.1 mg kg‐1)
Study: 12392582
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.1 mg kg‐1)
Study: 7493374
Drug: 131I-labeled hMN-14
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 131I-labeled hMN-14 IgG (8 to 30 mCi, 0.5 to 20.0 mg)
Study: 7493374
Drug: hMN-14 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMN-14 (3 injections)
Study: 7493374
Drug: Tumor radiation
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor radiation absorbed dose
Study: 2372154
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg buprenorphine every 6 h for 36 h
Study: 2372154
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine every 6 h for 36 h
Study: 6765526
Drug: Purified pork
Normalized name: Insulin purified pork
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purified pork insulin preparation (regular and NPH insulin)
Study: 6765526
Drug: Purified beef
Normalized name: Insulin purified beef
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purified beef insulin (regular and NPH insulin)
Study: 25654959
Drug: Levofloxacin (LFX)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin (LFX) 500 mg o.d. with scaling and root planing (SRP)
Study: 19106241
Drug: Higher insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher insulin dose
Study: 17454224
Drug: L-arginine (20g/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (20g/500 mL intravenously daily for 5 days followed by 4 g/day orally for 2 weeks)
Study: 15253854
Drug: Attitudes to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attitudes to Alternative Medicine Scale (pre-proving)
Study: 15253854
Drug: Attitudes to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attitudes to Alternative Medicine Scale (post-proving)
Study: 11238428
Drug: IEC interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IEC interventions with improved treatment of STDs
Study: 2660551
Drug: Sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 2 g B.I.D.
Study: 28537325
Drug: Calcium 1000
Normalized name: RITE AID Calcium 1000mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1000 mg/d and cholecalciferol 800 IU for 3 years (intervention group)
Study: 25482425
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg FXI‐ASO
Study: 25482425
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg FXI‐ASO
Study: 19366271
Drug: Candesartan/HCTZ 32/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan/HCTZ 32/25 mg
Study: 16712531
Drug: Endotracheal intubation
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal intubation attempted by paramedics without appropriate drugs to facilitate intubation.
Study: 16712531
Drug: Intubation facilitated
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubation facilitated by sedative drugs (but not relaxant drugs).
Study: 11046203
Drug: Hetastarch (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetastarch (15 ml/kg, 6%)
Study: 11046203
Drug: Albumin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (15 ml/kg, 5%)
Study: 8370687
Drug: Pamidronate (APD)
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate (APD) 30 mg, iv, daily for 2 days
Study: 2942116
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol and ipratropium (combined treatment)
Study: 2942116
Drug: Nebulised doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised doses (both treatments)
Study: 20180613
Drug: Antidepressants (sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (sertraline or citalopram) with or without cognitive behavioral therapy
Study: 20180613
Drug: Nonpharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic therapy (aerobic exercise)
Study: 8561153
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 1 day (n=10)
Study: 8561153
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 3 days (n=10)
Study: 8561153
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 5 days (n=10)
Study: 8561153
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 7 days (n=10)
Study: 1888322
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (for treated phobics)
Study: 1888322
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (for untreated phobics)
Study: 1888322
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (for no-fear controls)
Study: 7036285
Drug: Immunotherapy (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (combined BCG arms)
Study: 23213075
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (SMT)
Study: 19075102
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg/d
Study: 19075102
Drug: simvastatin/ezetimibe 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin/ezetimibe 10/10 mg/d
Study: 17824295
Drug: Carni Q-gel
Normalized name: Carni Q-Gel Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carni Q-gel (2250 mg/d L-carnitine and 270 mg/d hydrosoluble ubiquinol) for 12 weeks
Study: 17824295
Drug: Carni Q-gel
Normalized name: Carni Q-Gel Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carni Q-gel
Study: 9793589
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 750 mg/5 mL with normal breakfast (fat content 21 g)
Study: 9793589
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 750 mg/5 mL with Sustacal Plus (fat content 28 g)
Study: 9793589
Drug: Atovaquone suspension
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone suspension 750 mg/5 mL fasting
Study: 408142
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose on day 4 (n = 6)
Study: 408142
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg glucagon with glucose load on day 4 (n = 5)
Study: 408142
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glucagon with glucose load on day 4 (n = 6)
Study: 408142
Drug: Glucagon administered
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon administered 24 h after glucose load (n = 6)
Study: 26051429
Drug: Olive leaf
Normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive leaf extract (OLE) (51 mg oleuropein; 10 mg HT)
Study: 21083582
Drug: Itopride 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 50 mg
Study: 21083582
Drug: Itopride 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 100 mg
Study: 19690227
Drug: On-demand use
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand use of antibiotics
Study: 17224857
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg drospirenone/1 mg estradiol (DRSP/E2)
Study: 11885213
Drug: Outpatient women-centered
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient women-centered substance abuse treatment program
Study: 9782691
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (treatment group)
Study: 7869251
Drug: L-NMMA (nitric
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (nitric oxide synthase blocker)
Study: 7869251
Drug: Atropine +
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine + L-NMMA
Study: 7869251
Drug: Control (contralateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (contralateral forearm without treatment)
Study: 31102326
Drug: Glimepiride (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1-3 mg/day)
Study: 31129812
Drug: L-selenomethionine (L-Se-Met)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-selenomethionine (L-Se-Met) 83 mcg/day
Study: 26056515
Drug: Regular beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular beer (up to 660 ml) followed by water ad-libitum (BW)
Study: 21659972
Drug: Risedronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35 mg once a week) + 600 mg calcium + 400 IU vitamin D
Study: 21659972
Drug: Control (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (600 mg calcium + 400 IU vitamin D)
Study: 17448262
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone (GnRH) analogues
Study: 12969167
Drug: Fosinopril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril, 10 mg/day
Study: 1333909
Drug: Suspension injection
Normalized name: Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension injection alone (A, n = 54)
Study: 1333909
Drug: Suspension injection
Normalized name: Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension injection + TAE using gelatin sponge (B, n = 29)
Study: 1333909
Drug: TAE followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAE followed by suspension injection (C, n = 34)
Study: 6385745
Drug: Optimal oral
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal oral nutrition
Study: 29324495
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (2 mg/kg for 15 minutes followed by 2 mg/kg/h)
Study: 29324495
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (20 mg/kg over 15 minutes followed by 20 mg/kg/h)
Study: 26792372
Drug: Intravenous Zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous Zoledronic acid
Study: 12575396
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) combined with captopril (CAP)
Study: 2439255
Drug: Intraoperative colloids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative colloids (0.5 g/kg)
Study: 29101402
Drug: Sertraline (n=102)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (n=102) at an initial dose of 50 mg/d, escalated to a maximum of 200 mg/d for 12 weeks
Study: 29101402
Drug: Sertraline (n=102)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (n=102)
Study: 23293335
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (1 infusion)
Study: 23293335
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (3 infusions)
Study: 17898344
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment for up to 14 weeks
Study: 18288090
Drug: Next-step treatment
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next-step treatment after citalopram
Study: 18288090
Drug: Third-step treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Third-step treatment among those with unsatisfactory benefit to citalopram and one next-step pharmacotherapy
Study: 16547529
Drug: Broad-based immunomodulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-based immunomodulatory agents (e.g. intravenous immunoglobulin, thalidomide, pentoxifylline)
Study: 1439112
Drug: Thymostimulin (Tp-1)
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (Tp-1) treatment
Study: 24336664
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural group therapy (10 sessions)
Study: 10673735
Drug: Newer antihypertensive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antihypertensive agents (amlodipine and perindopril)
Study: 10673735
Drug: Older antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older antihypertensive agents (bendroflumethiazide and atenolol)
Study: 9104123
Drug: Cairwave Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cairwave Therapy System
Study: 31584782
Drug: Halobetasol 0.01%
Normalized name: HALOBETASOL 0.01%/TAZAROTENE 0.045% LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol 0.01% lotion
Study: 27181998
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once daily (S100)
Study: 27181998
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice daily (M1000)
Study: 27181998
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice daily (M1700)
Study: 27181998
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg twice daily plus Metformin 500 mg twice daily (S100/M1000)
Study: 27181998
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg twice daily plus Metformin 850 mg twice daily (S100/M1700)
Study: 27181998
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin groups
Study: 12618970
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg azithromycin once daily for 3 days
Study: 12618970
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg erythromycin stearate every 6 hours for 3 days
Study: 6303001
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg propranolol (Dociton)
Study: 6303001
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg metoprolol (Beloc)
Study: 31418425
Drug: Call center
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Call center intervention providing information about MR medications
Study: 19299533
Drug: Tedisamil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil (100 mg bid)
Study: 19299533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tedisamil and verapamil
Study: 19299533
Drug: Verapamil (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (180 mg bid)
Study: 19299533
Drug: Tedisamil and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil and verapamil combination
Study: 19299533
Drug: Verapamil and
Normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil and tedisamil combination
Study: 12113382
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol 9 microg twice daily
Study: 14682413
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline 400 mg once daily
Study: 9925123
Drug: High-fiber meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber meal (15.7 g fiber) containing barley pasta enriched with beta-glucan
Study: 9925123
Drug: Low-fiber meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber meal (5.0 g fiber) containing pasta made with wheat flour
Study: 7672999
Drug: Intramuscular 800
Normalized name: Peptimax 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 800 mg (5 ml) human immunoglobulin (1x/week)
Study: 7672999
Drug: Panthenol (4x10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panthenol (4x10 ml/day) and nystatin (4 x 1 ml/day)
Study: 7234648
Drug: Diltiazem (D)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (D) 240 mg
Study: 31446157
Drug: Yohimbine (alpha2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (alpha2-receptor antagonist)
Study: 24079281
Drug: rosuvastatin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (maximum dose of 10 mg for <10 years, 20 mg for older children)